Lynn C Hartmann

US Patent:

7470509, Dec 30, 2008

Filed:

Feb 7, 2003

Appl. No.:

10/361112

Inventors:

Andrew I. Damokosh - West Hartford CT, US
Natalia Iartchouk - Wayland MA, US
Edwin A. Clark - Pennington NJ, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Gordon B. Mills - Houston TX, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q 1/68

US Classification:

435 6, 536 231, 536 235, 435 4

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.

US Patent:

7871775, Jan 18, 2011

Filed:

Dec 17, 2007

Appl. No.:

12/002783

Inventors:

Edwin Clark - Ashland MA, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US

Assignee:

Millennium Pharmaceuticals, Inc - Cambridge MA
Mayo Foundation for Medical Edication and Research - Rochester MN
Board of Regents, The University of Texas System - Austin TX

International Classification:

C12Q 1/68

US Classification:

435 6, 536 231

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers. ” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers. ” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

US Patent:

8486412, Jul 16, 2013

Filed:

Jun 1, 2007

Appl. No.:

12/303054

Inventors:

Keith L. Knutson - Rochester MN, US
Lynn C. Hartmann - Rochester MN, US
Kimberly R. Kalli - Dover MN, US
Christopher J. Krco - Rochester MN, US

Assignee:

Mayo Foundation for Medical Education and Research - Rochester MN

International Classification:

A61K 38/10
C07K 4/12

US Classification:

4241851, 4241841, 4242771, 514 192, 514 193, 514 214, 514 215, 530326, 530806

Abstract:

This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FRα immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.

US Patent:

20030143552, Jul 31, 2003

Filed:

Feb 8, 2002

Appl. No.:

10/071510

Inventors:

Edwin Clark - Ashland MA, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey Brown - Arlington MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q001/68
G01N033/574

US Classification:

435/006000, 435/007230

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of sensitivity and resistance markers. These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

US Patent:

20090081710, Mar 26, 2009

Filed:

Mar 30, 2006

Appl. No.:

11/887438

Inventors:

Philip Stewart Low - West Lafayette IN, US
Lynn C. Hartmann - Rochester MN, US
Christopher Paul Leamon - West Lafayette IN, US
Phil Ronald Ellis - West Lafayette IN, US

Assignee:

Purdue Research Foundation - West Lafayette IN

International Classification:

G01N 33/574

US Classification:

435 723

Abstract:

The invention relates to a method for determining a prognosis for a cancer by quantifying vitamin receptor expression on the cancer cells. The method comprises the steps of quantifying vitamin receptor expression on the cancer cells, and determining a prognosis for the cancer. The invention also relates to methods and kits for determining the presence of vitamin receptors on cancer cells to select patients that should be treated with a therapy that utilizes vitamin receptor targeting and to develop a treatment regimen for such patients. The invention further relates to kits for performing the methods.

US Patent:

20090136961, May 28, 2009

Filed:

Nov 18, 2008

Appl. No.:

12/313196

Inventors:

Andrew I. Damokosh - West Hortford CT, US
Edwin A. Clark - Ashland MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Gordon B. Mills - Houston TX, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
Board of Regents - Austin TX
Mayo Foundation for Medical Education and Research - Rochester MN

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.

US Patent:

20100311106, Dec 9, 2010

Filed:

Jan 21, 2009

Appl. No.:

12/863889

Inventors:

Lynn C. Hartmann - Rochester MN, US
Carol Reynolds - Rochester MN, US
Kevin P. McKian - Rochester MN, US

International Classification:

C12Q 1/02

US Classification:

435 29

Abstract:

Methods for determining risk of developing breast cancer are described.

US Patent:

20110136129, Jun 9, 2011

Filed:

Dec 6, 2010

Appl. No.:

12/960894

Inventors:

Lynn C. Hartmann - Rochester MN, US
Marlene Frost - Burnsville MN, US
Carol Reynolds - Rochester MN, US
Vernon Pankratz - Rochester MN, US

International Classification:

C12Q 1/68

US Classification:

435 614

Abstract:

This document provides methods and materials involved in assessing the risk of developing breast cancer in patients with atypical hyperplasia. For example, methods and materials for using the level of Ki67 expression (e.g., percent Ki67cells or Ki67 staining intensity) to determine if a patient with atypical hyperplasia has an increased risk of developing breast cancer within an early phase from diagnosis (e.g., within ten years of biopsy) or an increased risk of developing breast cancer at a late phase from diagnosis (e.g., at a point more than ten years of biopsy) are provided.